Abstract:Liquid-Liquid phase separation (LLPS) of p53 to form liquid condensates has been implicated in cellular functions and dysfunctions. The p53 condensates may serve as amyloid fibril precursors to initiate p53 aggregation, which is associated with oncogenic gain-of-function and various human cancers. M237I and R249S mutations located in p53 core domain (p53C) have been detected respectively in glioblastomas and hepatocellular carcinoma. Interestingly, these p53C mutants can also undergo LLPS and liquid-to-solid phase transition, which are faster than wild type p53C. However, the underlying molecular basis governing the accelerated LLPS and liquid-to-solid transition of p53C remain poorly understood. Herein, we explore the M237I/R249S mutation-induced structural alterations and phase separation behavior of p53C by employing multiscale molecular dynamics simulations. All-atom simulations revealed conformational disruptions in the zinc-binding domain of the M237I mutant and in both loop3 and zinc-binding domain of the R249S mutant. The two mutations enhance hydrophobic exposure of those regions and attenuate intramolecular interactions, which may hasten the LLPS and aggregation of p53C. Martini 3 coarse-grained simulations demonstrated spontaneous phase separation of p53C and accelerated effects of M237I/R249S mutations on the phase separation of p53C. Importantly, we find that the regions with enhanced intermolecular interactions observed in coarse-grained simulations coincide with the disrupted regions with weakened intramolecular interactions observed in all-atom simulations, indicating that M237I/R249S mutation-induced local structural disruptions expedite the LLPS of p53C. This study unveils the molecular mechanisms underlying the two cancer-associated mutation-accelerated LLPS and aggregation of p53C, providing avenues for anticancer therapy by targeting the phase separation process.

Oncogenic R248W Mutation Induced Conformational Perturbation of the P53 Core Domain and the Structural Protection by Proteomimetic Amyloid Inhibitor ADH-6

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Mechanistic Insight into the Destabilization of P53td Tetramer by Cancer-Related R337H Mutation: a Molecular Dynamics Study.

Elucidating the Mechanisms of R248Q Mutation-Enhanced p53 Aggregation and Its Inhibition by Resveratrol

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Unraveling The Allosteric Mechanism Of Four Cancer-Related Mutations In The Disruption Of P53-Dna Interaction

Multisite Aggregation Of P53 And Implications For Drug Rescue

Conformational Stability and Dynamics of the Cancer‐associated Isoform Δ133p53β Are Modulated by P53 Peptides and P53‐specific DNA

Li-Fraumeni Syndrome-Associated Dimer-Forming Mutant P53 Promotes Transactivation-Independent Mitochondrial Cell Death.

Self-Aggregation And Coaggregation Of The P53 Core Fragment With Its Aggregation Gatekeeper Variant

Gain of Function of Mutant P53 by Coaggregation with Multiple Tumor Suppressors

Oncogenic Phase Transitions: How Mutant p53 Drives Amyloid Formation in p63 and p73 Liquid Droplets

Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators

Structural modulation of p53TAD1-TAZ2 complex upon mutations and post-translational modification

Full-atomistic Molecular Dynamics Analysis of p53 Active Tetramer

Oncogenic p53 triggers amyloid aggregation of p63 and p73 liquid droplets

Targeting mutant p53 stabilization for cancer therapy

Promising Proteolysis-Targeting Chimera for Mutant p53-R175H

Interdiction in the Early Folding of the p53 DNA-Binding Domain Leads to Its Amyloid-Like Misfolding

Protein adduction causes non-mutational inhibition of p53 tumor suppressor

Multiscale simulations reveal the driving forces of p53C phase separation accelerated by oncogenic mutations